World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
84
Citations
34594
World Ranking
14890
National Ranking
578

Sara Lonardi publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Sara Lonardi sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 740 publications — 84th percentile

84% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Sara Lonardi D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Sara Lonardi sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 84 D-Index — 27th percentile

27% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Sara Lonardi is affiliated with the Istituto Oncologico Veneto in Italy. Their research primarily spans the field of Medicine, with significant contributions in Oncology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine, Surgery, and Cancer Research.

Their scholarly work addresses a range of main topics, including:

  • Colorectal Cancer Treatments and Studies
  • Genetic factors in colorectal cancer
  • Gastric Cancer Management and Outcomes
  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Lung Cancer Treatments and Mutations

Some recent papers featuring contributions linked to their research interest include:

  • The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer, 2021, Nature
  • Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial, 2023, The Lancet
  • Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial, 2020, The Lancet Oncology
  • The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials, 2020, British Journal of Cancer
  • Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study, 2023, The Lancet Oncology

Sara Lonardi frequently collaborates with several authors, including:

  • Filippo Pietrantonio
  • Chiara Cremolini
  • Francesca Bergamo
  • Matteo Fassan
  • Gianluca Masi

Their publications are often found in key journals such as:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • European Journal of Cancer
  • ESMO Open
  • Cancers

Best Publications

  • Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

    Michael J. Overman;Ray McDermott;Joseph L. Leach;Sara Lonardi

  • Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer

    Michael J. Overman;Sara Lonardi;Ka Yeung Mark Wong;Heinz Josef Lenz

  • Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

    Scott Kopetz;Axel Grothey;Rona Yaeger;Eric Van Cutsem

  • FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

    Chiara Cremolini;Fotios Loupakis;Carlotta Antoniotti;Cristiana Lupi

  • Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

    Fotios Loupakis;Chiara Cremolini;Gianluca Masi;Sara Lonardi

  • Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial

    Andrea Sartore-Bianchi;Livio Trusolino;Cosimo Martino;Katia Bencardino

  • Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study

    Josep Tabernero;Takayuki Yoshino;Allen Lee Cohn;Radka Obermannova

  • Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial

    Carlo Aschele;Luca Cionini;Sara Lonardi;Carmine Pinto

  • Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.

    Chiara Cremolini;Daniele Rossini;Emanuela Dell’Aquila;Sara Lonardi

  • Assessment of a HER2 scoring system for colorectal cancer: results from a validation study

    Emanuele Valtorta;Cosimo Martino;Andrea Sartore-Bianchi;Frédérique Penaullt-Llorca

  • Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

    Chiara Cremolini;Carlotta Antoniotti;Daniele Rossini;Sara Lonardi

  • Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.

    Charles S Fuchs;Kohei Shitara;Maria Di Bartolomeo;Sara Lonardi

  • First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.

    Heinz-Josef Lenz;Eric Van Cutsem;Maria Luisa Limon;Ka Yeung Mark Wong

  • FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer

    F. Loupakis;C. Cremolini;L. Salvatore;G. Masi

  • Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)

    E Franceschi;G Cavallo;S Lonardi;E Magrini

  • Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest

    Chiara Cremolini;Fotios Loupakis;Carlotta Antoniotti;S. Lonardi

  • BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis

    C Cremolini;M. Di Bartolomeo;A. Amatu;C. Antoniotti

  • The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials.

    Giovanni Fucà;Vincenzo Guarini;Carlotta Antoniotti;Federica Morano

  • A phase I–II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer

    C. Aschele;M. L. Friso;S. Pucciarelli;S. Lonardi

  • BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection.

    Marta Schirripa;F. Bergamo;Chiara Cremolini;M. Casagrande

Frequent Co-Authors

Vittorina Zagonel
Vittorina Zagonel Mario Negri Institute for Pharmacological Research
Fotios Loupakis
Fotios Loupakis Istituto Oncologico Veneto
Alfredo Falcone
Alfredo Falcone University of Pisa
Matteo Fassan
Matteo Fassan University of Padua
Heinz-Josef Lenz
Heinz-Josef Lenz University of Southern California
Stefano Cascinu
Stefano Cascinu Vita-Salute San Raffaele University
Andrea Sartore-Bianchi
Andrea Sartore-Bianchi University of Milan
Filippo de Braud
Filippo de Braud University of Milan
Daniele Santini
Daniele Santini Università Campus Bio-Medico
Giuseppe Tonini
Giuseppe Tonini Università Campus Bio-Medico

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in medicine but wanting flexibility or alternative specializations, online health degrees offer diverse pathways. Many reputable schools now offer fully online programs, making it easier to balance studies with other commitments.

Those interested in mental health can consider online pmhnp programs, which prepare nurses to become psychiatric-mental health nurse practitioners. Administration-focused students might explore a health care administration degree online for roles leading hospitals or health systems.

Affordability is a key concern—fortunately, there are cheapest mha programs online healthcare and many low-cost master’s options to control tuition expenses. For advanced nursing careers, the best online bsn to dnp programs allow registered nurses to achieve a Doctor of Nursing Practice on a flexible schedule.

Carefully research accreditation, career outcomes, and program reputation to ensure your online degree will help you achieve your goals in medicine or healthcare.

Best Scientists Citing Sara Lonardi

Trending Scientists

Recently Published Articles